Generex Biotechnology Corp. (GNBT)
| Market Cap | 31.86M |
| Revenue (ttm) | 1.17M |
| Net Income (ttm) | n/a |
| Shares Out | 116.19M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $0.2772 |
| Previous Close | $0.2840 |
| Change ($) | -0.0068 |
| Change (%) | -2.39% |
| Day's Open | 0.2736 |
| Day's Range | 0.2711 - 0.2900 |
| Day's Volume | 180,344 |
| 52-Week Range | 0.1650 - 0.8500 |
MIRAMAR, Fla., May 05, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company wit...
MIRAMAR, Fla., May 04, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company wit...
MIRAMAR, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) subsidiary Olaregen Therapeutix today announced that the company has executed a Distribut...
MIRAMAR, Fla., April 12, 2021 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO – www.nugenerexio.com), a subsidiary of Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex” o...
NEW YORK, April 08, 2021 (GLOBE NEWSWIRE) -- Last Chance for Children's (LCFC) Mission is to help save children's lives anywhere in the world. Due to the COVID-19 pandemic we are now focusing our effort...
MIRAMAR, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB: GNBT) (“Generex or the “Company”), an innovative and integrated healthcare holding company with end-to-end sol...
MIRAMAR, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has compl...
The access information for the investor conference call is as follows: Domestic US/Canada - 1-(866) 342-8588Direct Toll / International - 1-(203) 518-9865 Program Title: Generex Biotechnology Conference...
MIRAMAR, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday February 5, 2021...
MIRAMAR, Fla., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that its majority owned pub...
MIRAMAR, Fla., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) and subsidiary NuGenerex Immuno-Oncology to...
MIRAMAR, Fla., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has...
MIRAMAR, Fla., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has...
MIRAMAR, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has signed...
MIRAMAR, Fla., Nov. 03, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation ( www.gen erex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/G...
Ii-Key technology is safe, and in a breast cancer trial 10 years out, still effective. GNBT is negotiating contracts covering these areas: Malaysia, New Zealand, Australia, Southeast Asia, Singapore, So...
-Dr. Tamera Coyne-Beasley, MD, MPH, FAAP, FSAHM is the Derrol Dawkins, MD Endowed Chair in Adolescent Medicine at Children's of Alabama, Professor of Pediatrics and Internal Medicine, Director of the Un...
Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design
MIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for tomorrow’s investor conference call on Thursday Octo...
MIRAMAR, Fla., Oct. 07, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/...
MIRAMAR, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has formed...
MIRAMAR, Fla., Oct. 02, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology (http://nugenerexio.com) is pleased to announce that the company will hold a shareholder conference call on Thursday October 8t...
- NuGenHealth Software as a Service (SaaS) platform launch - PVFM responds to COVID-19 with connected care solutions to serve their Medicare patient population
MIRAMAR, Fla., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) is pleased to announce that the comp...
Article Published on September 8, 2020:
Generex Biotechnology's COVID-19 vaccine is potentially superior to leading competition.
About GNBT
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, i... [Read more...]
| Industry Biotechnology | Founded 1983 |
| CEO Joseph Moscato | Employees 15 |
| Stock Exchange OTCMKTS | Ticker Symbol GNBT |